Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

PURPOSE: Immunotherapy is regarded as the most promising treatment for cancer. However, immune checkpoint inhibitors (ICIs) are not effective for all patients. Herein, we conducted a systematic review and meta-analysis to explore whether tumor mutational burden (TMB) can be used as a potential progn...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Taobi, Chen, Xia, Zhang, Huiyun, Liang, Yuan, Li, Longquan, Wei, Hui, Sun, Weiming, Wang, Yuping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358612/
https://www.ncbi.nlm.nih.gov/pubmed/34395281
http://dx.doi.org/10.3389/fonc.2021.706652

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8358612/
https://www.ncbi.nlm.nih.gov/pubmed/34395281
http://dx.doi.org/10.3389/fonc.2021.706652

Ejemplares similares